New combo therapy aims to boost survival in elderly lung cancer patients
NCT ID NCT06656598
First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This study tests whether giving immunotherapy (Cemiplimab) along with chemotherapy (Carboplatin and Paclitaxel) before radiation can help elderly or unfit patients with stage III non-small cell lung cancer live longer without their cancer getting worse. The trial will enroll 152 participants and compare this approach to standard care. The goal is to improve survival while keeping side effects manageable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Carboplatin, Paclitaxel, Cemiplimab (Libtayo), and hypofractionated radiotherapy
- What this could lead to
- If successful, this could offer a more effective treatment option for elderly or unfit patients with stage III lung cancer, potentially improving survival without the need for more aggressive therapy.
- What could go wrong
- This is an early Phase 2 trial with only 152 participants, so results may not apply to all patients. The combination of drugs and radiation may cause side effects like fatigue, low blood counts, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Angers - CHU
RECRUITINGAngers, France
Contact Email: •••••@•••••
-
Angers - Centre Paul Papin
RECRUITINGAngers, France
Contact Email: •••••@•••••
-
Avignon - CH
RECRUITINGAvignon, France
Contact Email: •••••@•••••
-
Bordeaux - CHU
RECRUITINGPessac, France
Contact Email: •••••@•••••
-
Boulogne - Ambroise Paré
RECRUITINGBoulogne, France
Contact Email: •••••@•••••
-
Brest - CHU
RECRUITINGBrest, France
Contact Email: •••••@•••••
-
Caen - CHU
RECRUITINGCaen, France
Contact Email: •••••@•••••
-
Caen - CRLCC
RECRUITINGCaen, France
Contact Email: •••••@•••••
-
Créteil - CHI
RECRUITINGCréteil, France
Contact Email: •••••@•••••
-
Dijon - CRLCC
RECRUITINGDijon, France
Contact Email: •••••@•••••
-
Le Mans - CHG
RECRUITINGLe Mans, France
Contact Email: •••••@•••••
-
Lille - CRLCC
RECRUITINGLille, France
Contact Email: •••••@•••••
-
Lyon - HCL
RECRUITINGPierre-Bénite, France
Contact Email: •••••@•••••
-
Marseille - APHM
RECRUITINGMarseille, France
Contact Email: •••••@•••••
-
Mulhouse - GHRMSA
RECRUITINGMulhouse, France
Contact Email: •••••@•••••
-
Nantes - CRLCC
RECRUITINGSaint-Herblain, France
Contact Email: •••••@•••••
-
Paris - Bichat
RECRUITINGParis, France
Contact Email: •••••@•••••
-
Paris - Hôpital Cochin
RECRUITINGParis, France
Contact Email: •••••@•••••
-
Paris - Tenon
RECRUITINGParis, France
Contact Email: •••••@•••••
-
Rennes - CHU
RECRUITINGRennes, France
Contact Email: •••••@•••••
-
Rouen - Centre Henri Becquerel
RECRUITINGRouen, France
Contact Email: •••••@•••••
-
Strasbourg - CRLCC
RECRUITINGStrasbourg, France
Contact Email: •••••@•••••
-
Toulouse - CHU
RECRUITINGToulouse, France
Contact Email: •••••@•••••
-
Tours - CHU
RECRUITINGTours, France
Contact Email: •••••@•••••
-
Vandoeuvre-lès-Nancy - CRLCC
RECRUITINGVandœuvre-lès-Nancy, France
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.